Poland's Artillery Ambition
Poland is investing $663 million to dramatically increase production of artillery shells, creating ripple effects across the defense industry. These carefully selected stocks represent companies throughout the supply chain poised to benefit from this strategic shift in defense spending.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
General Dynamics Corporation
GD
Current price
$316.40
A leading U.S. producer of 155mm artillery shells and other munitions, directly benefiting from increased NATO-wide demand for these specific munition...
A leading U.S. producer of 155mm artillery shells and other munitions, directly benefiting from increased NATO-wide demand for these specific munitions.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Poland's massive investment to quintuple artillery shell production signals a broader NATO rearmament trend in response to the Ukraine conflict. This creates long-term growth opportunities across the defense supply chain, from major contractors to specialized component manufacturers.
What You Need to Know
This collection offers exposure to a specific geopolitical trend reshaping defense priorities. The stocks represent the full artillery supply chain – from raw materials and components to complete systems and targeting technologies – spanning both European and US markets.
Why These Stocks
These companies were selected for their direct connection to artillery production and the broader defense modernization cycle. They include prime contractors producing complete systems, specialized manufacturers of key components, and suppliers of critical materials needed for increased production.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+5.46%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 5.46% over the next year.
Stocks Rated Buy by Analysts
10 of 12 assets in this group are rated Buy by professional analysts.
Group Growth
This group averaged a 0.5% return last month.
Why You'll Want to Watch These Stocks
Defense Budgets Are Booming
NATO countries are rapidly increasing military spending after years of underinvestment. Poland's $663 million artillery initiative is just one example of this larger, long-term trend.
Supply Chain Shortages Create Opportunity
The defense industry is scrambling to increase production capacity after decades of consolidation. Companies that can deliver critical components and materials are positioned for significant growth.
This Goes Beyond Poland
This investment theme captures the ripple effects across Europe and the US as allies coordinate to strengthen NATO's eastern flank. The artillery focus offers unique exposure to a specific, high-demand segment.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.